Connecticut-based Great Point Partners has been an active investor in pharmaceutical infrastructure since 2010. Great Point Partners has made investments in multiple companies; Caption Proteomics, Cytovance Biologics, Corrona and Softbox.
Pharmaceutical infrastructure is key in serving the logistical needs of the medical industry. The daunting task of using limited resources often leads companies to outsource key areas of their logistical pipeline. These can include maintenance on equipment, transportation and shipping needs for finished products, and managing energy services for manufacturing facilities.
These investments in infrastructure occur throughout the supply chain for biotech companies. Everything from patient records to pharmaceutical manufacturing provides ample opportunity for growth and the potential for significant returns for savvy investors.